Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

NCT04185038 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT04185038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04185038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 11, 2019
Completion date
May 31, 2042
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, central nervous system tumor, choroid plexus carcinoma, diffuse intrinsic pontine glioma, diffuse midline glioma, ependymoma, germ cell tumor, glioma, medulloblastoma, childhood, pineoblastoma, childhood, primitive neuroectodermal tumor